MYGN Insider Trading Activity and SEC Form 4 Filings
Trump's trades in MYGN
From his financial disclosures
-
0 purchases
$15K+
1 sale
Sale
Mar 23, 2026
Reported 52d later
$15K - $50K
Many orders in these accounts are placed by the account manager.
MYGN insider trading summary
Over the past 12 months, insiders at Myriad Genetics Inc (MYGN) reported 2 open-market purchases worth $227K by 2 insiders and 1 sale worth $67K by 1 insider on SEC Form 4. Net insider buying was $161K.
Latest MYGN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Rashmi Kumar | Director | Sell | $67K (15,000 @ $4.46) |
| May 14, 2026 | Paul Bisaro | Director | Buy | $28K (7,500 @ $3.69) |
| Mar 9, 2026 | Samraat S. Raha | President and CEO | Buy | $200K (40,000 @ $5.00) |
| Oct 11, 2024 | Paul J Diaz | President and CEO | Sell | $344K (15,000 @ $22.93) |
| Sep 11, 2024 | Paul J Diaz | President and CEO | Sell | $401K (15,000 @ $26.72) |
| Sep 11, 2024 | Dale Muzzey | Chief Scientific Officer | Sell | $55K (2,100 @ $26.17) |
| Sep 9, 2024 | Heinrich Dreismann | Director | Sell | $271K (10,000 @ $27.05) |
| Sep 3, 2024 | Colleen F Reitan | Director | Sell | $1.3M (46,012 @ $27.95) |
| Aug 21, 2024 | Margaret Ancona | SVP, Chief of Staff | Sell | $321K (11,538 @ $27.82) |
| Aug 19, 2024 | Rashmi Kumar | Director | Sell | $210K (7,500 @ $28.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.